DNLI logo

Denali Therapeutics (DNLI) Cash From Operations

Annual CFO

-$357.99 M
-$113.28 M-46.29%

December 31, 2023

Summary

Performance

1-Year Change

-46.29%

3-Year Change

-186.02%

5-Year Change

-814.32%

15-Year Change

-367.14%

DNLI Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

2.04%
DNLI annual cash flow from operations is higher than 2.04% of companies in Healthcare sector

High & Low

All-time High

$416.15 M
DNLI annual cash flow from operations is currently -186.02% below its historical high of $416.15 million

3-Year Low

-$357.99 M
DNLI annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
DNLI previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 27, 2025
DNLI next annual earnings announcement is scheduled for Feb 27, 2025

OtherDNLIcash flowmetrics:

Annual CFI

$249.31 M
DNLI annual cash flow from investing activities is $249.31 million

Annual CFF

$17.82 M
DNLI annual cash flow from financing activities is $17.82 million

Annual FCF

-$370.93 M
DNLI annual free cash flow is -$370.93 million

Annual CAPEX

$12.94 M
DNLI annual capital expenditures is $12.94 million

Quarterly CFO

-$59.14 M
+$32.08 M+35.17%

September 30, 2024

Summary

Performance

3-Month Change

+35.17%

1-Year Change

+35.17%

3-Year Change

+18.61%

5-Year Change

+18.61%

DNLI Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

4.98%
DNLI quarterly cash flow from operations is higher than 4.98% of companies in Healthcare sector

High & Low

All-time High

$513.91 M
DNLI quarterly cash flow from operations is currently -111.51% below its historical high of $513.91 million

3-Year Low

-$113.62 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DNLI previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
DNLI next earnings announcement is scheduled for Feb 27, 2025

OtherDNLIcash flowmetrics:

Quarterly CFI

$93.66 M
DNLI quarterly cash flow from investing activities is $93.66 million

Quarterly CFF

-$18.56 M
DNLI quarterly cash flow from financing activities is -$18.56 million

Quarterly FCF

-$63.02 M
DNLI quarterly free cash flow is -$63.02 million

Quarterly CAPEX

-
DNLI quarterly capital expenditures value is unknown

TTM CFO

-$362.64 M
+$28.22 M+7.22%

September 30, 2024

Summary

Performance

3-Month Change

+7.22%

1-Year Change

+7.22%

3-Year Change

-48.19%

5-Year Change

-48.19%

DNLI TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

1.83%
DNLI TTM cash flow from operations is higher than 1.83% of companies in Healthcare sector

High & Low

All-time High

$420.40 M
DNLI TTM cash flow from operations is currently -186.26% below its historical high of $420.40 million

3-Year Low

-$412.81 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DNLI previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
DNLI next earnings announcement is scheduled for Feb 27, 2025

OtherDNLIcash flowmetrics:

TTM CFI

-$187.92 M
DNLI TTM cash flow from investing activities is -$187.92 million

TTM CFF

$493.18 M
DNLI TTM cash flow from financing activities is $493.18 million

TTM FCF

-$375.69 M
DNLI TTM free cash flow is -$375.69 million

TTM CAPEX

-
DNLI TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

DNLI Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-46.3%+35.2%+7.2%
3 y3 years-186.0%+18.6%-48.2%
5 y5 years-814.3%+18.6%-48.2%

DNLI Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-69.3%at low-37.9%+48.0%-71.5%+12.2%
5 y5-year-186.0%at low-111.5%+48.0%-186.3%+12.2%
alltimeall time-186.0%at low-111.5%+48.0%-186.3%+12.2%

Denali Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$59.14 M(-35.2%)
-$362.64 M(-7.2%)
Jun 2024
-
-$91.22 M(-19.7%)
-$390.86 M(-5.3%)
Mar 2024
-
-$113.62 M(+15.2%)
-$412.81 M(+15.3%)
Dec 2023
-$357.99 M(+46.3%)
-$98.66 M(+12.9%)
-$357.99 M(+7.8%)
Sep 2023
-
-$87.36 M(-22.8%)
-$332.00 M(+10.0%)
Jun 2023
-
-$113.17 M(+92.5%)
-$301.68 M(+30.4%)
Mar 2023
-
-$58.80 M(-19.1%)
-$231.41 M(-5.4%)
Dec 2022
-$244.72 M(+15.8%)
-$72.66 M(+27.4%)
-$244.72 M(+3.0%)
Sep 2022
-
-$57.05 M(+33.0%)
-$237.55 M(+7.0%)
Jun 2022
-
-$42.90 M(-40.5%)
-$221.94 M(-4.9%)
Mar 2022
-
-$72.11 M(+10.1%)
-$233.26 M(+10.3%)
Dec 2021
-$211.39 M(-150.8%)
-$65.49 M(+58.1%)
-$211.39 M(-157.4%)
Sep 2021
-
-$41.43 M(-23.6%)
$368.02 M(-10.1%)
Jun 2021
-
-$54.22 M(+7.9%)
$409.54 M(-2.6%)
Mar 2021
-
-$50.24 M(-109.8%)
$420.40 M(+1.0%)
Dec 2020
$416.15 M
$513.91 M(>+9900.0%)
$416.15 M(-386.2%)
DateAnnualQuarterlyTTM
Sep 2020
-
$86.00 K(-100.2%)
-$145.41 M(-17.3%)
Jun 2020
-
-$43.36 M(-20.4%)
-$175.93 M(+0.1%)
Mar 2020
-
-$54.49 M(+14.4%)
-$175.75 M(+15.9%)
Dec 2019
-$151.58 M(-402.5%)
-$47.64 M(+56.5%)
-$151.58 M(+1310.3%)
Sep 2019
-
-$30.43 M(-29.5%)
-$10.75 M(-29.0%)
Jun 2019
-
-$43.17 M(+42.4%)
-$15.13 M(+9.8%)
Mar 2019
-
-$30.32 M(-132.5%)
-$13.78 M(-127.5%)
Dec 2018
$50.12 M(-165.4%)
$93.19 M(-367.6%)
$50.12 M(-181.6%)
Sep 2018
-
-$34.82 M(-16.7%)
-$61.41 M(+26.6%)
Jun 2018
-
-$41.82 M(-224.6%)
-$48.50 M(+100.0%)
Mar 2018
-
$33.58 M(-283.1%)
-$24.25 M(-68.4%)
Dec 2017
-$76.64 M(+6.6%)
-$18.34 M(-16.4%)
-$76.64 M(+31.5%)
Sep 2017
-
-$21.92 M(+24.8%)
-$58.30 M(+60.3%)
Jun 2017
-
-$17.57 M(-6.6%)
-$36.38 M(+93.4%)
Mar 2017
-
-$18.81 M
-$18.81 M
Dec 2016
-$71.91 M(+377.7%)
-
-
Dec 2015
-$15.05 M
-
-

FAQ

  • What is Denali Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Denali Therapeutics?
  • What is Denali Therapeutics annual CFO year-on-year change?
  • What is Denali Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Denali Therapeutics?
  • What is Denali Therapeutics quarterly CFO year-on-year change?
  • What is Denali Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Denali Therapeutics?
  • What is Denali Therapeutics TTM CFO year-on-year change?

What is Denali Therapeutics annual cash flow from operations?

The current annual CFO of DNLI is -$357.99 M

What is the all time high annual CFO for Denali Therapeutics?

Denali Therapeutics all-time high annual cash flow from operations is $416.15 M

What is Denali Therapeutics annual CFO year-on-year change?

Over the past year, DNLI annual cash flow from operations has changed by -$113.28 M (-46.29%)

What is Denali Therapeutics quarterly cash flow from operations?

The current quarterly CFO of DNLI is -$59.14 M

What is the all time high quarterly CFO for Denali Therapeutics?

Denali Therapeutics all-time high quarterly cash flow from operations is $513.91 M

What is Denali Therapeutics quarterly CFO year-on-year change?

Over the past year, DNLI quarterly cash flow from operations has changed by +$32.08 M (+35.17%)

What is Denali Therapeutics TTM cash flow from operations?

The current TTM CFO of DNLI is -$362.64 M

What is the all time high TTM CFO for Denali Therapeutics?

Denali Therapeutics all-time high TTM cash flow from operations is $420.40 M

What is Denali Therapeutics TTM CFO year-on-year change?

Over the past year, DNLI TTM cash flow from operations has changed by +$28.22 M (+7.22%)